- CONMED Corporation recently appointed Andrew Moller, a certified public accountant and former Smith & Nephew Global Controller and CFO Asia-Pacific, as Interim Principal Financial Officer effective March 15, 2026, following his prior roles as Vice President, Corporate Controller and Principal Accounting Officer.
- This change in financial leadership arrives as CONMED faces slower revenue growth than many healthcare peers and an anticipated 1.3% sales decline over the coming year, raising questions about how finance leadership will respond to these operating pressures.
- Next, we’ll examine how appointing Andrew Moller as interim finance chief could influence CONMED’s investment narrative and outlook.
AI is about to change healthcare. These 36 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
CONMED Investment Narrative Recap
To own CONMED, you need to believe its minimally invasive surgery portfolio and core brands like AirSeal and BioBrace can translate into steady procedure demand despite recent revenue and earnings pressure. The appointment of Andrew Moller as Interim Principal Financial Officer does not materially change the near term catalyst, which is improving profitability after a difficult 2025, nor the key risk, which remains execution in a slower growth, highly competitive medtech market.
Among recent developments, CONMED’s decision in December 2025 to exit its gastroenterology product lines and transition VIABIL stent distribution to Olympus stands out. This portfolio reshaping is closely tied to the same earnings and margin story that Moller will now help oversee, and it directly affects how effectively CONMED can focus resources on higher priority businesses that support its core growth and margin catalysts.
Yet even with these changes, one risk that investors should be aware of is the potential for prolonged margin pressure if...
Read the full narrative on CONMED (it's free!)
CONMED's narrative projects $1.6 billion revenue and $154.0 million earnings by 2028. This requires 5.7% yearly revenue growth and a roughly $43.8 million earnings increase from $110.2 million today.
Uncover how CONMED's forecasts yield a $48.40 fair value, a 32% upside to its current price.
Exploring Other Perspectives
Compared with the consensus view, the most pessimistic analysts already assumed only about US$1.5 billion in 2028 revenue and US$127.4 million in earnings, and they worry that rising global healthcare cost controls could tighten reimbursement and squeeze pricing even further. This new finance leadership move could push those expectations in either direction, which is why it is worth looking at how different analysts frame CONMED’s next few years.
Explore 3 other fair value estimates on CONMED - why the stock might be worth over 2x more than the current price!
Reach Your Own Conclusion
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your CONMED research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision.
- Our free CONMED research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CONMED's overall financial health at a glance.
Curious About Other Options?
Our daily scans reveal stocks with breakout potential. Don't miss this chance:
- The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
- Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
- Find 55 companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com